Download PDF
Thromb Haemost 1974; 32(02/03): 468-482
DOI: 10.1055/s-0038-1647715
Original Article
Schattauer GmbH

Acute Deep Vein Thrombosis Treated with Porcine Plasmin

A Double Blind Trial
O Storm
1   Surgical Department D, Glostrup Hospital, Copenhagen, Denmark
,
P Ollendorff
1   Surgical Department D, Glostrup Hospital, Copenhagen, Denmark
,
E Drewsen
1   Surgical Department D, Glostrup Hospital, Copenhagen, Denmark
,
P Tang
1   Surgical Department D, Glostrup Hospital, Copenhagen, Denmark
› Author Affiliations
Further Information

Publication History

Received: 04 February 1974

Accepted after resubmission 28 July 1974

Publication Date:
30 June 2018 (online)

    Permissions and Reprints

Summary

The thrombolytic effect of pig plasmin was tested in a double blind trial on patients with deep venous thrombosis in the lower limb. Only patients with not more than three days old thrombi were selected for this study. The diagnosis of deep vein thrombosis was made clinically and confirmed by phlebography. Lysofibrin Novo (porcine plasmin) or placebo (porcine plasminogen) was administered intravenously to the patients. The enzyme and the placebo were delivered as lyophilized powder in labelled bottles - the contents of the bottles were unknown to the doctor in charge of the clinical administration of the trial. An initial dose of plasmin/plasminogen of 30 unit per kg body weight given slowly intravenously (1-1% hours infusion) was followed by a maintenance dosis of 15 per cent the initial dose per hour for the following 5-7 hours. In most cases a similar maintenance dosis was given the next day. In all patients heparin was administered after ending the plasmin/plasminogen infusion. The results of the treatment was evaluated clinically as well as by control phlebo- grams the following days.

A statistically significant improvement was found in the plasmin treated group compared with the placebo (plasminogen) treated group. Thrombolysis was obtained clinically and phlebographically in 65 per cent of the plasmin treated group, but only in 15 per cent of the control patients were improvements found.

This study has thus demonstrated that plasmin treatment according to a standard scheme was able to induce thrombolysis. There were only a few and insignificant side effects. Allergic reactions have not been seen and only very simple tests are required.

 

  • References

  • 1 Aiæijaersig N, Fletcher A. P, Sherry S. 1959; The mechanism of clot dissolution by plasmin. The Journal of Clinical Investigation 38: 1086.
    CrossrefPubMedGoogle Scholar
  • 2 Amris C. J, Larsen V, Bröckner J. 1966; Scheme for fibrinolytic treatment with activator-free porcine plasmin. The Scandinavian Jonrnal of Clinical and Laboratory Investigation 18 supplement 89, 24.
    PubMedGoogle Scholar
  • 3 Amris C. J, Larsen V, Mogensen B, Storm O. 1963; Infusion of porcine plasmin in man. Studies on toxicology and pharmacodynamics. The Scandinavian Journal of Clinical and Laboratory Investigation 15: 179.
    PubMedGoogle Scholar
  • 4 Amris C. J, Larsen V, Mogensen B, Storm O. 1964; Effect of plasmin therapy on blood coagulation and on plasma proteins in patients with cancer. Danish Medical Bulletin 11: 141.
    PubMedGoogle Scholar
  • 5 Amris C. J, Larsen V, Mogensen B, Storm O. 1964; Turnover and distribution of 131 J-labelled porcine plasmin in man and dog. Danish Medical Bulletin 11: 146.
    PubMedGoogle Scholar
  • 6 Astrup T, Brakman P, Nissen U. 1965; The estimation of fibrinogen. A revision Scandivavian Journal of Clinical and Laboratory Investigation 17: 57.
    PubMedGoogle Scholar
  • 7 Back N, Ambrus J. L, Simpson C. L, Schulman S. 1958; Study on the effect of streptokinase activated plasmin (fibrinolysin) on clots in various stages or organization. Journal of Clinical Investigation 37: 864.
    CrossrefPubMedGoogle Scholar
  • 8 Brakman P, Albrechtsen O. K, Astrup T. 1966; A comparative study of coagulation and fibrinolysis in blood from normal men and women. British Journal of Haematology 12: 74.
    CrossrefPubMedGoogle Scholar
  • 9 Fantl P. 1962; Plasminogen activity of plasma and serum. Science 135: 787.
    CrossrefPubMedGoogle Scholar
  • 10 Fischer M. 1971; Möglichkeiten der thrombolytischen Therapie. Wiener Klinische Wochenschrift 83: 277.
    PubMedGoogle Scholar
  • 11 Gormsen J. 1972; Treatment of acute phlebothrombosis with streptokinase according to a standard scheme. Ugeskrift for Laeger 134: 1322.
    PubMedGoogle Scholar
  • 12 Gottlob R, Blümel G. 1966; Über den Nachweis der Plasminogenverarmung in retrahierten Vollblutgerinnseln und über deren Bedeutung für die Lysierbarkeit mit Streptokinase. Thrombosis et Diathesis Haemorrhagica 15: 570.
    PubMedGoogle Scholar
  • 13 Hedner U, Nilsson I. M, Robertson B. 1966; Determination of plasminogen in clots and thrombi. Thrombosis and Diathesis Haemorrhagica 16: 38.
    PubMedGoogle Scholar
  • 14 Johnson A. J, Kline D. L, Alkjaersig N. 1969; Assay Methods and Standard Preparations for Plasmin, Plasminogen, and Urokinase in Purified Systems 1967-1968. Thrombosis et Diathesis Haemorrhagica 21: 259.
    PubMedGoogle Scholar
  • 15 Kakkar Y. V, Flanc C, Howe C. T, O’Shea M, Flute P. T. 1969; Treatment of deep vein thrombosis. A trial of heparin, streptokinase, and arvin. British Medical Journal I: 806.
    PubMedGoogle Scholar
  • 16 Lee R. I, White P. D. 1913; A clinical study of the coagulation of blood. American Journal of Medical Science 145: 495.
    CrossrefPubMedGoogle Scholar
  • 17 Merskey C, Kleiner G. J, Johnson A. J. 1966; Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment. Blood 28: 1.
    PubMedGoogle Scholar
  • 18 Ogston D, Ogston C. M, Fullerton H. W. 1966; The plasminogen content of thrombi. Thrombosis and Diathesis Haemorrhagica 15: 220.
    PubMedGoogle Scholar
  • 19 Olow B, Johanson C, Andersson J, Eklöf B. 1970; Deep venous thrombosis treated with a standard dosage of streptokinase. Acta Chirurgica Scandinavica 136: 181.
    PubMedGoogle Scholar
  • 20 Owren P. A. 1947; The Coagulation of Blood: Investigation on a New Clotting Factor. Acta Medica Scandinavica Suppl. 194.
    PubMedGoogle Scholar
  • 21 Owren P. A. 1959; Thrombotest, A New Method for Controlling Anticoagulant Therapy. Lancet 02: 754.
    PubMedGoogle Scholar
  • 22 Quick A. J. 1935; The Prothrombin in Haemophilia and in Obstructive Jaundice. Journal Biological Chemistry 109: 73.
    PubMedGoogle Scholar
  • 23 Robertson B, Nilsson I. M, Nylander G. 1970; Thrombolytic effect of streptokinase as evaluated by phlebography of deep venous thrombi of the leg. Acta Chirurgica Scandinavica 136: 173.
    PubMedGoogle Scholar
  • 24 Schmutzler R, Koller F. 1969. Thrombolytic Therapy. In Poller L. (ed.) Recent Advances in Blood Coagulation. J. and A. Churchill Ltd; London: 299.
    Google Scholar
  • 25 Sokal J. E, Ambrus J. L, Ambrus C. M. 1958; The treatment of thrombosis with plasmin. Journal American Medical Association 168: 1314.
    CrossrefPubMedGoogle Scholar
  • 26 Storm O, Amris C. J, Larsen V, Mogensen B. 1962. Klinische Erfahrungen mit Plasmin Novo. In: Zukschwerdt L, Thies H. A. (ed.) V Hamburger Symposium über Blutgerinnung, Thrombosis et Diathesis Haemorrhagica. 7, suppl. 3, 179.
    Google Scholar
  • 27 Storm O, Larsen V, Mogensen B. 1961; Plasmin therapy combined with anticoagulants in severe thrombo-embolic conditions. Acta Chirurgica Scandinavica 123 suppl. 283, 315.
    PubMedGoogle Scholar